WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 4 fonti

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small...

Raccontata da

markets.businessinsider.com

biopharmadive.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

markets.businessinsider.comStai leggendo1 mesi fa

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small...

Timeline cronologica

venerdì 22 maggio 2026·markets.businessinsider.com
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small...
venerdì 22 maggio 2026·statnews.com
Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.

biopharmadive.com

1 mesi fa

Parkinson’s drug from Biogen, Denali comes up short

High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

Leggi questa versione → originale

endpoints.news1 mesi fa

Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients.

Leggi questa versione → originale

statnews.com1 mesi fa

Closely watched experimental Parkinson’s drug fails key clinical trial

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.

Leggi questa versione → originale

venerdì 22 maggio 2026·

biopharmadive.com

Parkinson’s drug from Biogen, Denali comes up short

High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of…

venerdì 22 maggio 2026·

endpoints.news

Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients.